ASX:MSBMesoblast Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Mesoblast limited Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day RangeA$3.39MA: A$3.39▼A$3.3952-Week Range N/AVolume10.19 million shsAverage Volume2.19 million shsMarket Capitalization$1.82 billionP/E RatioN/ADividend YieldN/ABetaN/A ProfileChartCompetitorsEarningsInsider TradesHeadlinesOptions Chain Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Mesoblast. Previous Next 2.1 Community Rank Outperform VotesMesoblast has received 64 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMesoblast has received 88 “underperform” votes. (Add your “underperform” vote.)Community SentimentMesoblast has received 57.89% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote “Outperform” if you believe MSB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MSB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMesoblast does not currently pay a dividend.Dividend GrowthMesoblast does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mesoblast insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Mesoblast is -26.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mesoblast is -26.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioMesoblast has a PEG Ratio of 20.71. PEG Ratios above 1 indicate that a company could be overvalued. Previous Next Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.42 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:MSB Previous Symbol CUSIPN/A CIKN/A Webwww.mesoblast.com Phone+61-3-96396036Debt Debt-to-Equity Ratio19.63 Current Ratio0.91 Quick Ratio0.81Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth20.71 Sales & Book Value Annual Sales$33.42 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow30.00 Book ValueA$0.91 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees81 Outstanding Shares583,950,016Market Cap$1.82 billion Next Earnings Date8/27/2020 (Estimated) OptionableOptionable Receive MSB News and Ratings via Email Sign-up to receive the latest news and ratings for MSB and its competitors with MarketBeat's FREE daily newsletter. Mesoblast (ASX:MSB) Frequently Asked Questions When is Mesoblast's next earnings date? Mesoblast is scheduled to release its next quarterly earnings announcement on Thursday, August 27th 2020. View our earnings forecast for Mesoblast. How were Mesoblast's earnings last quarter? Mesoblast limited (ASX:MSB) released its quarterly earnings results on Thursday, February, 21st. The company reported ($0.09) EPS for the quarter. View Mesoblast's earnings history. Has Mesoblast been receiving favorable news coverage? News articles about MSB stock have trended extremely negative this week, according to InfoTrie. The research firm ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mesoblast earned a media sentiment score of -4.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Mesoblast. Who are some of Mesoblast's key competitors? Some companies that are related to Mesoblast include Vir Biotechnology (VIR), MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Actinium Pharmaceuticals (ATNM), Actinium Pharmaceuticals (ATNM), MorphoSys (MOR), Repare Therapeutics (BLI), BTG (BTG), Cronos Group (CRON), Abcam (ABC), Genus (GNS), Kodiak Sciences (KOD), Viela Bio (VIE), Polynovo (PNV) and NGM Biopharmaceuticals (NGM). View all competitors. What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Mesoblast (MESO), Alliance Resource Partners (ARLP), OceanaGold (OGC), Bubs Australia (BUB), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), GENFIT S A/ADR (GNFT), Pluristem Therapeutics (PSTI), Starpharma (SPL) and Viking Therapeutics (VKTX). Who are Mesoblast's key executives? Mesoblast's management team includes the following people: Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)Mr. Roger D. Brown BA, Head of Spinal Orthopedic DisordersMr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)Dr. Kenneth M. Borow M.D., Exec. (Age 71) What is Mesoblast's stock symbol? Mesoblast trades on the ASX under the ticker symbol "MSB." How big of a company is Mesoblast? Mesoblast has a market capitalization of $0.00 and generates $33.42 million in revenue each year. Mesoblast employs 81 workers across the globe. What is Mesoblast's official website? The official website for Mesoblast is www.mesoblast.com. How can I contact Mesoblast? Mesoblast's mailing address is L 38 55 Collins St, MELBOURNE, VIC 3000, Australia. The company can be reached via phone at +61-3-96396036. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
